The mission of the Mouse Pathology Core (the Core) is to provide histologic and hematopoietic research support services to UCSF Helen Diller Family Comprehensive Cancer Center (Center) investigators studying the pathogenesis and treatment of organ and hematologic malignancies in mouse models of human cancer. This facility provides services for members of many of the Center's programs. Histology services performed by the manager and staff include processing, embedding, and histologic sectioning of murine tissues in paraffin and frozen blocks (with re-embedding of tissue as necessary);routine histochemical staining (hematoxylin and eosin);and other special histochemical stains. In addition to providing both training on and access to the equipment utilized for pathologic analysis of murine tissues, the Core also conducts a mouse pathology workshop that provides training in necropsy, dissection, tissue trimming, and sectioning techniques. Furthermore, the Core provides expertise in murine hematology. Complete blood counts are provided for investigators, including preparation of blood smears for analysis of white blood cell, red blood cell, and platelet morphology. Another service provided by the Core is access to outside veterinary laboratory testing (e.g., serum chemistry assays). The Core also facilitates pathologic consultation for researchers provided by the Co-Directors, Drs. Coussens and Kogan. Offering consultation with the Co- Directors makes available the same expertise an in-house murine pathologist would provide, including aid in planning experiments, and expertise in data analysis at a greatly reduced cost to the organization. The Core was used by laboratory personnel representing approximately 50 different investigators at the Center, providing a total of 8533 units of service during the most recent 12 month period (January 2010 through December 2010). Investigators in many of the Center programs have relied upon the Core not only for direct services, but also for training of their personnel. Demonstration of the utility and expertise of the Core is evident by extensive publications reflecting use of mouse models of human cancer by investigators that utilize this service.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-14
Application #
8388378
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-08-05
Project End
2017-05-31
Budget Start
2012-09-19
Budget End
2013-05-31
Support Year
14
Fiscal Year
2012
Total Cost
$128,017
Indirect Cost
$46,260
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Autry, Adam; Phillips, Joanna J; Maleschlijski, Stojan et al. (2017) Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol 10:895-903
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
de Smith, Adam J; Kaur, Maneet; Gonseth, Semira et al. (2017) Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia. Cancer Res 77:1674-1683
Stieglitz, Elliot; Mazor, Tali; Olshen, Adam B et al. (2017) Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 8:2127
Bartlett, Thomas E; Müller, Sören; Diaz, Aaron (2017) Single-cell Co-expression Subnetwork Analysis. Sci Rep 7:15066
Martin, Thomas; Baz, Rachid; Benson, Don M et al. (2017) A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 129:3294-3303
Zhang, Jie; Yao, Tsun-Wen; Hashizume, Rintaro et al. (2017) Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. J Neurooncol 131:495-505
Li, Megan; Kroetz, Deanna L (2017) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther :
Aggarwal, Rahul; Behr, Spencer C; Paris, Pamela L et al. (2017) Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res 15:1221-1229

Showing the most recent 10 out of 168 publications